Frequency and percentage of self-reported medical late effects comparing siblings with patients by chronic graft-versus-host disease status (limited to most frequent outcomes associated with chronic GVHD)
. | . | Chronic GVHD . | . | No chronic GHVD . | . | ||
|---|---|---|---|---|---|---|---|
. | Siblings, no. (%) . | No. (%) . | P versus siblings . | No. (%) . | P versus siblings . | ||
| No. | 317 (100.0) | 95 (100.0) | — | 153 (100.0) | — | ||
| Eye impairments | 36 (11.4) | 58 (61.1) | < .001 | 63 (41.2) | < .001 | ||
| Cataracts | 12 (3.8) | 49 (51.6) | < .001 | 46 (30.1) | < .001 | ||
| Very dry eyes | 26 (8.2) | 37 (38.9) | < .001 | 25 (16.3) | .01 | ||
| Oral health impairments | 41 (12.9) | 38 (40.0) | < .001 | 28 (18.3) | .13 | ||
| Dry mouth | 3 (0.9) | 17 (17.9) | < .001 | 17 (11.1) | < .001 | ||
| Problems chewing or swallowing | 4 (1.3) | 17 (17.9) | < .001 | 7 (4.6) | .08 | ||
| Endocrine impairments | 35 (11.0) | 28 (29.5) | < .001 | 35 (22.9) | < .001 | ||
| Hypothyroid | 23 (7.3) | 21 (22.1) | < .001 | 16 (10.5) | .15 | ||
| Diabetes | 9 (2.8) | 10 (10.5) | .01 | 20 (13.1) | < .001 | ||
| Bone and joint health | 8 (2.5) | 19 (20.0) | < .001 | 12 (7.8) | .01 | ||
| Osteoporosis | 7 (2.2) | 14 (14.7) | < .001 | 10 (6.5) | .03 | ||
| Avascular necrosis | 1 (0.3) | 7 (7.4) | .01 | 2 (1.3) | .32 | ||
| Cardiopulmonary impairments | 82 (25.9) | 41 (43.2) | .001 | 40 (26.1) | .99 | ||
| Exercise-induced shortness of breath | 8 (2.5) | 14 (14.7) | .001 | 9 (5.9) | .10 | ||
| Gastrointestinal impairments | 29 (9.1) | 20 (21.1) | .006 | 23 (15.0) | .07 | ||
| Neurosensory impairments | 64 (20.2) | 46 (48.4) | < .001 | 54 (35.3) | .001 | ||
| Loss of, or abnormal sense of, taste/smell | 2 (0.6) | 27 (28.4) | < .001 | 19 (12.4) | < .001 | ||
| Loss of, or abnormal sense of, touch | 30 (9.5) | 27 (28.4) | < .001 | 26 (17.0) | .03 | ||
| Neuromotor impairments | 19 (6.0) | 28 (29.5) | < .001 | 23 (15.0) | .004 | ||
| Balance, tremor, or weakness | 16 (5.0) | 27 (28.4) | < .001 | 23 (15.0) | .001 | ||
. | . | Chronic GVHD . | . | No chronic GHVD . | . | ||
|---|---|---|---|---|---|---|---|
. | Siblings, no. (%) . | No. (%) . | P versus siblings . | No. (%) . | P versus siblings . | ||
| No. | 317 (100.0) | 95 (100.0) | — | 153 (100.0) | — | ||
| Eye impairments | 36 (11.4) | 58 (61.1) | < .001 | 63 (41.2) | < .001 | ||
| Cataracts | 12 (3.8) | 49 (51.6) | < .001 | 46 (30.1) | < .001 | ||
| Very dry eyes | 26 (8.2) | 37 (38.9) | < .001 | 25 (16.3) | .01 | ||
| Oral health impairments | 41 (12.9) | 38 (40.0) | < .001 | 28 (18.3) | .13 | ||
| Dry mouth | 3 (0.9) | 17 (17.9) | < .001 | 17 (11.1) | < .001 | ||
| Problems chewing or swallowing | 4 (1.3) | 17 (17.9) | < .001 | 7 (4.6) | .08 | ||
| Endocrine impairments | 35 (11.0) | 28 (29.5) | < .001 | 35 (22.9) | < .001 | ||
| Hypothyroid | 23 (7.3) | 21 (22.1) | < .001 | 16 (10.5) | .15 | ||
| Diabetes | 9 (2.8) | 10 (10.5) | .01 | 20 (13.1) | < .001 | ||
| Bone and joint health | 8 (2.5) | 19 (20.0) | < .001 | 12 (7.8) | .01 | ||
| Osteoporosis | 7 (2.2) | 14 (14.7) | < .001 | 10 (6.5) | .03 | ||
| Avascular necrosis | 1 (0.3) | 7 (7.4) | .01 | 2 (1.3) | .32 | ||
| Cardiopulmonary impairments | 82 (25.9) | 41 (43.2) | .001 | 40 (26.1) | .99 | ||
| Exercise-induced shortness of breath | 8 (2.5) | 14 (14.7) | .001 | 9 (5.9) | .10 | ||
| Gastrointestinal impairments | 29 (9.1) | 20 (21.1) | .006 | 23 (15.0) | .07 | ||
| Neurosensory impairments | 64 (20.2) | 46 (48.4) | < .001 | 54 (35.3) | .001 | ||
| Loss of, or abnormal sense of, taste/smell | 2 (0.6) | 27 (28.4) | < .001 | 19 (12.4) | < .001 | ||
| Loss of, or abnormal sense of, touch | 30 (9.5) | 27 (28.4) | < .001 | 26 (17.0) | .03 | ||
| Neuromotor impairments | 19 (6.0) | 28 (29.5) | < .001 | 23 (15.0) | .004 | ||
| Balance, tremor, or weakness | 16 (5.0) | 27 (28.4) | < .001 | 23 (15.0) | .001 | ||
— indicates not applicable.